ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from ...
New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil ...
Encapsulating human stem-cell-derived beta cells in microcapsules made with an immune-cell-repelling protein restored glucose metabolism in diabetic mice and protected the cells from immune system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results